Pharmacodynamic assessment of Amoxicillin-Sulbactam against Acinetobacter baumannii: searching the optimal dose and infusion time through a human ex-vivo model

Amoxicillin-sulbactam (AMX-SUL) is an aminopenicillin/ß-lactamase inhibitor combination currently available in 29 countries and may be a suitable option for treating infections caused by Acinetobacter spp. Thus, we sought to search the optimal dosing strategy for this formulation through an ex vivo...

Full description

Bibliographic Details
Main Authors: Carlos Bantar, Liliana Fernández Canigia, María Alejandra Berger, Jorge L Soutric, Héctor J Arenoso
Format: Article
Language:English
Published: Elsevier
Series:Brazilian Journal of Infectious Diseases
Subjects:
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702009000500006&lng=en&tlng=en
_version_ 1830486769479450624
author Carlos Bantar
Liliana Fernández Canigia
María Alejandra Berger
Jorge L Soutric
Héctor J Arenoso
author_facet Carlos Bantar
Liliana Fernández Canigia
María Alejandra Berger
Jorge L Soutric
Héctor J Arenoso
author_sort Carlos Bantar
collection DOAJ
description Amoxicillin-sulbactam (AMX-SUL) is an aminopenicillin/ß-lactamase inhibitor combination currently available in 29 countries and may be a suitable option for treating infections caused by Acinetobacter spp. Thus, we sought to search the optimal dosing strategy for this formulation through an ex vivo pharmacodynamic human model against Acinetobacter baumanniii. Four volunteers were randomized to receive alternatively a single dose AMX-SUL infused both either over 30 min or 3h at the following ratios (g/g): 1/0.5; 1/1, and 0/2. Time-kill studies were performed with the 0-, 0.5-, 2-, 4-, 6- and 8-h sera after dose against a clinical isolate of A. baumannii (sulbactam MIC, 4µg/mL). Bactericidal activity (i.e. a mean decrease >3 log10 CFU/mL in the viable cell counts from the initial inoculum) was displayed by the 0.5- and the 2-h sera after dose for all formulations. The 4-h sera proved inhibitory with the AMX-SUL 1g/1g formulation, albeit a trend to regrowth was observed after 24-h incubation. With the AMX-SUL 0g/2g dose, the 4-h sera proved almost bactericidal activity (i.e. a mean decrease of 2.4 log10 CFU/mL in the viable cell counts from the initial inoculum), whereas the 6-h sera was inhibitory, with a trend to regrowth after 24-h incubation. When infused over 3h, AMX-SUL 1g/0.5g and 1g/1g, bactericidal activity was displayed by the 0.5-, 2- and the 4-h sera after dose and the 6-h sera proved inhibitory with the AMX-SUL 1g/1g formulation. The present study, albeit preliminary, might give a rationale for the dosing strategy to treat infections caused by A. baumannii with sulbactam, either alone or combined with amoxicillin. A 2-g sulbactam dose seems to be optimal to be infused over 30 min with a 6-h dosing interval. When infused over 3h, AMX-SUL 1g/1g given every 6h or 8h seems a suitable dosing schedule.
first_indexed 2024-12-21T18:50:04Z
format Article
id doaj.art-1fe1fc58106f458f98e000b9b02aa67a
institution Directory Open Access Journal
issn 1678-4391
language English
last_indexed 2024-12-21T18:50:04Z
publisher Elsevier
record_format Article
series Brazilian Journal of Infectious Diseases
spelling doaj.art-1fe1fc58106f458f98e000b9b02aa67a2022-12-21T18:53:47ZengElsevierBrazilian Journal of Infectious Diseases1678-439113534835210.1590/S1413-86702009000500006S1413-86702009000500006Pharmacodynamic assessment of Amoxicillin-Sulbactam against Acinetobacter baumannii: searching the optimal dose and infusion time through a human ex-vivo modelCarlos Bantar0Liliana Fernández Canigia1María Alejandra Berger2Jorge L Soutric3Héctor J Arenoso4Laboratorio Domingo I NanniHospital AlemánHospital AlemánLaboratorios Bagó S.A.Laboratorios Bagó S.A.Amoxicillin-sulbactam (AMX-SUL) is an aminopenicillin/ß-lactamase inhibitor combination currently available in 29 countries and may be a suitable option for treating infections caused by Acinetobacter spp. Thus, we sought to search the optimal dosing strategy for this formulation through an ex vivo pharmacodynamic human model against Acinetobacter baumanniii. Four volunteers were randomized to receive alternatively a single dose AMX-SUL infused both either over 30 min or 3h at the following ratios (g/g): 1/0.5; 1/1, and 0/2. Time-kill studies were performed with the 0-, 0.5-, 2-, 4-, 6- and 8-h sera after dose against a clinical isolate of A. baumannii (sulbactam MIC, 4µg/mL). Bactericidal activity (i.e. a mean decrease >3 log10 CFU/mL in the viable cell counts from the initial inoculum) was displayed by the 0.5- and the 2-h sera after dose for all formulations. The 4-h sera proved inhibitory with the AMX-SUL 1g/1g formulation, albeit a trend to regrowth was observed after 24-h incubation. With the AMX-SUL 0g/2g dose, the 4-h sera proved almost bactericidal activity (i.e. a mean decrease of 2.4 log10 CFU/mL in the viable cell counts from the initial inoculum), whereas the 6-h sera was inhibitory, with a trend to regrowth after 24-h incubation. When infused over 3h, AMX-SUL 1g/0.5g and 1g/1g, bactericidal activity was displayed by the 0.5-, 2- and the 4-h sera after dose and the 6-h sera proved inhibitory with the AMX-SUL 1g/1g formulation. The present study, albeit preliminary, might give a rationale for the dosing strategy to treat infections caused by A. baumannii with sulbactam, either alone or combined with amoxicillin. A 2-g sulbactam dose seems to be optimal to be infused over 30 min with a 6-h dosing interval. When infused over 3h, AMX-SUL 1g/1g given every 6h or 8h seems a suitable dosing schedule.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702009000500006&lng=en&tlng=enAmoxicillin-sulbactamAcinetobacter
spellingShingle Carlos Bantar
Liliana Fernández Canigia
María Alejandra Berger
Jorge L Soutric
Héctor J Arenoso
Pharmacodynamic assessment of Amoxicillin-Sulbactam against Acinetobacter baumannii: searching the optimal dose and infusion time through a human ex-vivo model
Brazilian Journal of Infectious Diseases
Amoxicillin-sulbactam
Acinetobacter
title Pharmacodynamic assessment of Amoxicillin-Sulbactam against Acinetobacter baumannii: searching the optimal dose and infusion time through a human ex-vivo model
title_full Pharmacodynamic assessment of Amoxicillin-Sulbactam against Acinetobacter baumannii: searching the optimal dose and infusion time through a human ex-vivo model
title_fullStr Pharmacodynamic assessment of Amoxicillin-Sulbactam against Acinetobacter baumannii: searching the optimal dose and infusion time through a human ex-vivo model
title_full_unstemmed Pharmacodynamic assessment of Amoxicillin-Sulbactam against Acinetobacter baumannii: searching the optimal dose and infusion time through a human ex-vivo model
title_short Pharmacodynamic assessment of Amoxicillin-Sulbactam against Acinetobacter baumannii: searching the optimal dose and infusion time through a human ex-vivo model
title_sort pharmacodynamic assessment of amoxicillin sulbactam against acinetobacter baumannii searching the optimal dose and infusion time through a human ex vivo model
topic Amoxicillin-sulbactam
Acinetobacter
url http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702009000500006&lng=en&tlng=en
work_keys_str_mv AT carlosbantar pharmacodynamicassessmentofamoxicillinsulbactamagainstacinetobacterbaumanniisearchingtheoptimaldoseandinfusiontimethroughahumanexvivomodel
AT lilianafernandezcanigia pharmacodynamicassessmentofamoxicillinsulbactamagainstacinetobacterbaumanniisearchingtheoptimaldoseandinfusiontimethroughahumanexvivomodel
AT mariaalejandraberger pharmacodynamicassessmentofamoxicillinsulbactamagainstacinetobacterbaumanniisearchingtheoptimaldoseandinfusiontimethroughahumanexvivomodel
AT jorgelsoutric pharmacodynamicassessmentofamoxicillinsulbactamagainstacinetobacterbaumanniisearchingtheoptimaldoseandinfusiontimethroughahumanexvivomodel
AT hectorjarenoso pharmacodynamicassessmentofamoxicillinsulbactamagainstacinetobacterbaumanniisearchingtheoptimaldoseandinfusiontimethroughahumanexvivomodel